Abzena nets $300 million for its ThioBridge technology
January 20, 2017Abzena has made a deal with a San Diego-based biopharmaceutical company for Abzena’s novel site–specific ThioBridge antibody drug conjugate (ADC) linker technology, which links antibodies and other proteins to drugs.
The $300 million worth agreement with the San Diego company covers the use of ThioBridge in up to 10 ADCs across a wide range of indications. The deal also says that multiple programmes of work related to Abzena’s chemistry services can be undertaken for a certain extended period.
Abzena said that the deal could reach over $300 million with certain fees and milestone payments, as well as royalties on sales of products made with the ThioBridge technology developed by its partner.
Dr John Burt, CEO of Abzena, said: “Abzena and the US biopharmaceutical company has enjoyed an ongoing collaborative research programme to evaluate ThioBridge up until now. The collaboration has allowed both parties to build a strong working relationship and to demonstrate the value of the ThioBridge technology in creating novel ADCs. Signing this extensive licence agreement for ThioBridge is further validation of our proprietary ADC technology and expertise. We look forward to continuing to work together with our partner for the development of novel ThioBridge ADCs.”
Abzena did not say who the San Diego-based company is. We have asked the name of the company in an email to Abzena. We will update this article should we get the answer.
